CN102861086A - Application of Houttuynoid E in medicine for treating ovarian cancer - Google Patents
Application of Houttuynoid E in medicine for treating ovarian cancer Download PDFInfo
- Publication number
- CN102861086A CN102861086A CN2012104187179A CN201210418717A CN102861086A CN 102861086 A CN102861086 A CN 102861086A CN 2012104187179 A CN2012104187179 A CN 2012104187179A CN 201210418717 A CN201210418717 A CN 201210418717A CN 102861086 A CN102861086 A CN 102861086A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- ovarian cancer
- medicine
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid E in preparation of a medicine for treating human ovarian cancer, belonging to the technical field of new application of medicine. The invention discovers that Houttuynoid E has the remarkable inhibitory effects on the growth of human ovarian cancer cell strains, including HO-8910, HOC1 and OVAC through the evaluation of in vitro MTT antineoplastic activity. Therefore, Houttuynoid E can be used for preparing the anti-ovarian cancer medicine and has good development and application prospects. The application of Houttuynoid E in preparation of the medicine for treating human ovarian cancer provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the inhibitory activity of Houttuynoid E on human ovarian cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid E, relate in particular to the application of Houttuynoid E in the preparation ovarian cancer resistance medicament.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid E that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid E that the present invention relates in preparation treatment ovarian cancer medicine, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid E in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid E in the preparation ovarian cancer resistance medicament, and the structural formula of Houttuynoid E is shown in formula I:
Formula I
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid E also has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC, suppresses the IC of this 3 strain Growth of Cells
50Value is respectively 1.25 ± 0.07 μ M, 1.33 ± 0.07 μ M and 0.71 ± 0.06 μ M.Therefore, Houttuynoid E can for the preparation of ovarian cancer resistance medicament, have good development prospect.
The purposes of the Houttuynoid E that the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid E involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid E tablet involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid E capsule involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid E to human oophoroma cell line's growth inhibited effect
1. method: the cell that is in the growth logarithmic (log) phase: human oophoroma cell line HO-8910, HOC1 and OVAC(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid E of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid E has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.This chemical compound suppresses the IC of human oophoroma cell line HO-8910, HOC1 and OVAC growth
50Value is respectively: 1.25 ± 0.07 μ M, 1.33 ± 0.07 μ M and 0.71 ± 0.06 μ M.
Shown by above-described embodiment, Houttuynoid E of the present invention has good inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.Prove thus, Houttuynoid E of the present invention has the ovarian cancer resistance activity, can be for the preparation of ovarian cancer resistance medicament.
Claims (1)
1.Houttuynoid the application of E in treatment ovarian cancer medicine, described compound H outtuynoid E structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104187179A CN102861086A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in medicine for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104187179A CN102861086A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in medicine for treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102861086A true CN102861086A (en) | 2013-01-09 |
Family
ID=47440404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104187179A Pending CN102861086A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in medicine for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861086A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Composition comprising the extract of houttuynia cordata for treating or prevening cancer disease |
| US20120046237A1 (en) * | 1998-04-08 | 2012-02-23 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
| CN102448455A (en) * | 2009-03-31 | 2012-05-09 | 雀巢产品技术援助有限公司 | Use of flavonoids to increase the bioavailability of hesperetin |
-
2012
- 2012-10-27 CN CN2012104187179A patent/CN102861086A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120046237A1 (en) * | 1998-04-08 | 2012-02-23 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Composition comprising the extract of houttuynia cordata for treating or prevening cancer disease |
| CN102448455A (en) * | 2009-03-31 | 2012-05-09 | 雀巢产品技术援助有限公司 | Use of flavonoids to increase the bioavailability of hesperetin |
Non-Patent Citations (1)
| Title |
|---|
| 陈庆华等: "鱼腥草总黄酮的提取工艺研究", 《湖北中医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861097B (en) | Application of Houttuynoid E in medicine for treating bladder cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102861065A (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102861071B (en) | Application of Houttuynoid A in medicine for treating gastric cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102861073A (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102861086A (en) | Application of Houttuynoid E in medicine for treating ovarian cancer | |
| CN102861080A (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872073A (en) | Application of Houttuynoid C in drugs for treating ovarian cancer | |
| CN102861046A (en) | Application of Houttuynoid A in ovarian cancer treatment medicine | |
| CN102895247A (en) | Application of Houttuynoid B to medicament for treating oophoroma | |
| CN102861075A (en) | Application of Houttuynoid B in medicine for treating gastric cancer | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma | |
| CN102861064A (en) | Application of Houttuynoid E in medicine for treating laryngocarcinoma | |
| CN102861069A (en) | Application of Houttuynoid B in medicine for treating laryngocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130109 |